Therapeutic challenges in dystonia

Neurologic Clinics

Volumn 28, Issue 4, 2010, Pages 927-940

  Kartha, Ninith ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Deep brain stimulation; Dystonia; Therapy

Indexed keywords

BACLOFEN; BENZATROPINE; BENZODIAZEPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; CYCLOBENZAPRINE; DIAZEPAM; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ETIRACETAM; HALOPERIDOL; LEVODOPA; LORAZEPAM; PHENYTOIN; PIMOZIDE; RESERPINE; RISPERIDONE; TETRABENAZINE; TIZANIDINE; TRIHEXYPHENIDYL; VALPROIC ACID;

AGRANULOCYTOSIS; AKATHISIA; AMNESIA; ANXIETY; BLADDER DISEASE; BLEPHAROSPASM; BLURRED VISION; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DENERVATION; DEPRESSION; DIPLOPIA; DISEASE CLASSIFICATION; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRY EYE; DYSKINESIA; DYSPHAGIA; DYSTONIA; ENTEROPATHY; FOCAL DYSTONIA; GENERALIZED DYSTONIA; HUMAN; INFECTION; INJECTION SITE PAIN; INSOMNIA; LOW DRUG DOSE; MUSCLE RESECTION; NECK INJURY; NECK WEAKNESS; NERVOUSNESS; NONHUMAN; OCCUPATIONAL THERAPY; OROMANDIBULAR DYSTONIA; PALLIDOTOMY; PARKINSONISM; PHYSIOTHERAPY; PRIORITY JOURNAL; PTOSIS; REVIEW; SEDATION; SEGMENTAL DYSTONIA; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOICE CHANGE; XEROSTOMIA;

BOTULINUM TOXINS, TYPE A; DEEP BRAIN STIMULATION; DOPAMINE AGENTS; DYSTONIA; HUMANS; NEUROTOXINS;

EID: 77956259181     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.03.020     Document Type: Review

References (98)

1. Fahn S. Concept and classification of dystonia. Adv Neurol 1988, 50:1-8.
2. Jedynak C.P., Bennet A.M., Agid Y. Tremor and idiopathic dystonia. Mov Disord 1991, 6:230-236.
3. Trost M. Dystonia update. Curr Opin Neurol 2003, 16:495-500.
4. Berardelli A., Rothwell J.C., Hallett M., et al. The pathophysiology of primary dystonia. Brain 1998, 121:1195-1212.
5. Ikoma K., Samii A., Mercuri B., et al. Abnormal cortical motor excitability in dystonia. Neurology 1996, 46:1371-1376.
6. Lozano A.M., Kumar R., Gross R.E., et al. Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord 1997, 12:865-870.
7. Bressman S.B., Sabatti C., Raymond D., et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000, 54:1746-1752.
8. Greene P., Kang U.J., Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord 1995, 10:143-152.
9. Bressman S.B. Dystonia genotypes, phenotypes and classification. Adv Neurol 2004, 94:101-107.
10. Pettigrew L.C., Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatr 1985, 48:650-657.
11. Marsden C.D., Obeso J.A., Zarranz J.J., et al. The anatomical basis of symptomatic hemidystonia. Brain 1985, 108(Pt 2):463-483.
12. Bressman S.B., de Leon D., Brin M.F., et al. Idiopathic torsion dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol 1989, 26:612-620.
13. Opal P., Tintner R., Jankovic J., et al. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord 2002, 17:339-345.
14. Nutt J.G., Muenter M.D., Aronson A., et al. Epidemiology of focal and generalized dystonia in Rochester, MN. Mov Disord 1988, 3:188-194.
15. Warner T., Camfield L., Marsden C.D., et al. A prevalence study of primary dystonia in eight European countries. J Neurol 2000, 247:787-792.
16. Nakashima K., Kusumi M., Inoue Y., et al. Prevalence of focal dystonias in the western area of Tottori prefecture in Japan. Mov Disord 1995, 10:440-443.
17. Dung Le K., Niulsen B., Dietrichs E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003, 61:1294-1296.
18. Tolosa E., Marti M.J. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Adv Neurol 1988, 49:73-84.
19. Sheehy M.P., Marsden C.D. Writer's cramp: a focal dystonia. Brain 1982, 105:462-480.
20. Frucht S.J., Fahn S., Greene P.E., et al. The natural history of embouchure dystonia. Mov Disord 2001, 16:899-906.
21. Ichinose H., Ohye T., Takahashi E., et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994, 8:236-242.
22. Ludecke B., Dworniczak B., Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet 1995, 95:123-125.
23. Brashear A., Dobyns W.B., de Carvalho Aguiar P., et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A# gene. Brain 2007, 130:828-835.
24. Nygaard T.G., Raymond D., Chen C., et al. Localization of a gene for myoclonus-dystonia on chromosome 7q. Neurology 2001, 56:1213-1216.
25. Han F., Racacho L., Lang A.E., et al. Refinement of the DYT15 locus in myoclonus-dystonia. Mov Disord 2007, 22:888-892.
26. Saunders-Pullman R., Shriberg J., Heiman G., et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 2002, 58:242-245.
27. Friedman A., Fahn S. Spontaneous remissions in spasmodic torticollis. Neurology 1986, 36:398-400.
28. Jankovic J. Treatment of dystonia. Lancet Neurol 2006, 5:864-872.
29. Tassorelli C., Mancini F., Balloni L., et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 2006, 21:2240-2243.
30. Albanese A., Barnes M.P., Bhatia K.P., et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006, 13:433-444.
31. Nygaard T.G., Marsden C.D., Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991, 41:174-181.
32. Burke R.E., Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol 1983, 37:189-192.
33. Burke R.E., Fahn S., Marsden C.D. Torsion dystonia: a double-blind prospective trial of high-dosage trihexyphenidyl in dystonia. Neurology 1986, 36:160-164.
34. Lang A.E. High dose anticholinergic therapy in adult dystonia. Can J Neurol Sci 1986, 13:42-46.
35. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983, 33:1255-1261.
36. Greene P., Shale H., Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988, 50:547-556.
37. Nutt J.G., Hammerstad J.P., deGarmo P., et al. Cranial dystonia: double-blind crossover study of anticholinergics. Neurology 1984, 34:215-217.
38. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982, 11:41-47.
39. Jankovic J., Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358-362.
40. Burke R.E., Reches A., Traub M.M., et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985, 17:200-202.
41. Balash Y., Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004, 11:361-370.
42. Lang A.E. Dopamine agonists and antagonists in the treatment of idiopathic dystonia. Adv Neurol 1988, 50:561-570.
43. Karp B.I., Goldstein S.R., Chen R., et al. An open trial of clozapine for dystonia. Mov Disord 1999, 14:652-657.
44. Narayan R.K., Loubser P.G., Jankovic J., et al. Intrathecal baclofen for intractable axial dystonia. Neurology 1991, 41:1141-1142.
45. Walker R.H., Danisi F.O., Swope D.M., et al. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 2000, 15:1242-1247.
46. Ford B., Greene P.E., Louis E.D., et al. Intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996, 53:1241-1246.
47. Dalvi A., Fahn S., Ford B. Intrathecal baclofen in the treatment of dystonic storm. Mov Disord 1998, 13:611-612.
48. Mariotti P., Fasano A., Contarino F., et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007, 22:963-968.
49. Woon K., Tsegaye M., Vloeberghs M.H. The role of intrathecal baclofen in the management of primary and secondary dystonia in children. Br J Neurosurg 2007, 21:355-358.
50. Albright A.L., Barry M.J., Shafron D.H., et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001, 43:652-657.
51. Asmus F., Zimprich A., Tezenas Du Montel S., et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002, 52:489-492.
52. Greene P., Shale H., Fahn S. Analysis of open-label trials in torsion dystonia using high dosage of anticholinergics and other drugs. Mov Disord 1988, 3:46-60.
53. Snoeck J.W., van Weerden T.W., Teelken A.W., et al. Meige syndrome: double-blind crossover study of sodium valproate. J Neurol Neurosurg Psychiatr 1987, 50:1522-1525.
54. Lotze T., Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003, 10:68-79.
55. Zesiewicz T.A., Louis E.D., Sullivan K.L., et al. Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Mov Disord 2004, 19:1518-1521.
56. Sullivan K.L., Hauser R.A., Louis E.D., et al. Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005, 11:460-471.
57. Tarsy D., Ryan R.K., Ro S.I. An open-label trial of levetiracetam for treatment of cervical dystonia. Mov Disord 2006, 21:734-735.
58. Hering S., Wenning G.K., Seppi K., et al. An open trial of levetiracetam for segmental and generalized dystonia. Mov Disord 2007, 22:1649-1651.
59. Kuehn B. Studies, reports say botulinum toxin may have effects beyond injection site. JAMA 2008, 299:2261-2262.
60. Curra A., Berardelli A. Do the unintended actions of botulinum toxin at distant sites have clinical implications?. Neurology 2009, 72:1095-1099.
61. Kuehn B. FDA requires black box warnings on labeling for botulinum toxin products. JAMA 2009, 301:2316.
62. Jankovic J., Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987, 37:616-623.
63. Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol 2004, 94:275-286.
64. Greene P., Kang U., Fahn S., et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990, 40:1213-1218.
65. Comella C.L. The treatment of cervical dystonia with botulinum toxins. J Neural Transm 2008, 115:579-583.
66. Lew M.F., Adornato B.T., Duane D.D., et al. Botulinum toxin type B: a double-blind, placebo-controlled safety and efficacy study in cervical dystonia. Neurology 1997, 49:701-707.
67. Poewe W., Schelosky L., Kleedorfer B., et al. What is the optimal dose of botulinum toxin type A? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Study Group. J Neurol Neurosurg Psychiatr 1998, 64:13-17.
68. Comella C.L., Jankovic J., Shannon K.M., et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65:1423-1429.
69. Costa J., Espirito-Santo C., Borges A., et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 2005, 1. CD004900.
70. Cakmur R., Ozturk V., Uzunel F., et al. Comparison of preseptall and pretarsall injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002, 249:64-68.
71. Kenney C., Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008, 115:585-591.
72. Dashtipour K., Pender R.A. Evidence for the effectiveness of botulinum toxin for writer's cramp. J Neural Transm 2008, 115:653-656.
73. Kruisdijk J.J., Koelman J.H., Ongerboer de Vesser B.W., et al. Botulinum toxin for writer's cramp: a randomized, placebo-controlled trial and 1 year follow-up. J Neurol Neurosurg Psychiatr 2007, 78:264-270.
74. Watts C.R., Truong D.D., Nye C. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high quality research designs. J Neural Transm 2008, 115:625-630.
75. Truong D., Rontal M., Rolnick M., et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991, 101:630-634.
76. Moller E., Bakke M., Dalager T., et al. Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord 2007, 22:785-790.
77. Jankovic J., Esquenazi A., Fehling D., et al. Evidence-based review of patient reported outcomes with botulinum toxin type A. Clin Neuropharmacol 2004, 27:234-244.
78. Mejia N.I., Vuong K.D., Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 2005, 20:592-597.
79. Jankovic J., Vuong K.D., Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186-1188.
80. Bertrand C.M., Molina-Negro P., Bouvier G., et al. Observations and analysis of results in 131 cases of spasmodic torticollis after peripheral denervation. Appl Neurophysiol 1987, 50:319-323.
81. Bertrand C.M. Selective peripheral denervation for spasmodic torticollis: surgical techniques, results and observations in 260 cases. Surg Neurol 1993, 40:96-103.
82. Cohen-Gadol A.A., Ashklog J.E., Matsumoto J., et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg 2001, 98:1247-1254.
83. Munchau A., Palmer J.D., Dressler D. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain 2001, 123:769-783.
84. Vitek J.L. Mechanisms of deep brain stimulation: excitation or inhibition. Mov Disord 2002, 17(Suppl 3):S69-S72.
85. Vidailhet M., Vercueil L., Houeto J.L., et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005, 352:459-467.
86. Vidailhet M., Vercueil L., Houeto J.L., et al. Bilateral, pallidal, deep-brain stimulation in primary generalized dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007, 6:223-229.
87. Yianni J., Bain P.G., Gregory R.P., et al. Post-operative progress of dystonia patients following globus pallidus internus deep brain stimulation. Eur J Neurol 2003, 10:239-247.
88. Coubes P., Cif L., El Fertit H., et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. J Neurosurg 2004, 101:189-194.
89. Alterman A.L., Snyder B.J. Deep brain stimulation for torsion dystonia. Acta Neurochir Suppl 2007, 97:191-199.
90. Kupsch A., Benecke R., Muller J., et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006, 355:1978-1990.
91. Blahak C., Wohrle J.C., Capelle H.H., et al. Health-related quality of life in segmental dystonia is improved by bilateral pallidal stimulation. J Neurol 2008, 255:178-182.
92. Sensi M., Cavallo M., Quatrale R., et al. Pallidal stimulation for segmental dystonia: long term follow up of 11 consecutive patients. Mov Disord 2009, 24:1829-1835.
93. Krauss J.K., Pohle T., Weber S., et al. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet 1999, 354:837-838.
94. Parkin S., Aziz T., Gregory R., et al. Bilateral globus pallidus stimulation for the treatment of spasmodic torticollis. Mov Disord 2001, 16:489-493.
95. Eltahawy H.A., Saint-Cyr J., Poon Y.Y., et al. Pallidal deep brain stimulation in cervical dystonia: clinical outcome in 4 cases. Can J Neurol Sci 2004, 31:328-332.
96. Kiss Z.H.T., Doig-Beyaert K., Eliasziw M., et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007, 130:2879-2886.
97. Gruber D., Trottenberg T., Kivi A., et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009, 73:53-58.
98. Vidailhet M., Yelnick J., Lagrange C., et al. Bilateral pallidal deep brain stimulation of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet 2009, 8:709-717.